Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.48 |
| ▸ | TSPO | P30536 | 2/20 | 0.48 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.48 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14830633 | 0.86 | KIT (0.52) | MRGPRX1TSPOMAP2K4HRH1ACLY | |
| SCHEMBL15847815 | 0.80 | ACLY (0.51) | MRGPRX1TSPOACLYBRAFKMT2A | |
| SCHEMBL3336145 | 0.80 | BRAF (0.38) | MRGPRX1TSPOHRH1ACLYKIT | |
| SCHEMBL15847893 | 0.80 | ACLY (0.60) | MRGPRX1TSPOMAP2K4MAP2K7HRH1 | |
| SCHEMBL14830870 | 0.79 | PSIP1 (0.53) | MRGPRX1TSPOPOLBTSHR | |
| SCHEMBL26120220 | 0.79 | ATM (0.46) | MRGPRX1TSPOMAP2K4MAP2K7HRH1 | |
| SCHEMBL17465678 | 0.79 | ACLY (0.41) | MRGPRX1TSPOACLYBRAFKMT2A | |
| SCHEMBL15847536 | 0.77 | MRGPRX1 (0.59) | MRGPRX1TSPOMAP2K4HRH1BRAF | |
| SCHEMBL15847427 | 0.76 | ACLY (0.54) | MRGPRX1TSPOACLYBRAFPOLB | |
| SCHEMBL28045960 | 0.75 | MRGPRX1 (0.39) | MRGPRX1TSPOHRH1ACLYBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760845-B1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9376425-B2 | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer | AMGEN, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2014-08-21 | — | — | US | disclosed |
| EP-2760845-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049250-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235629-A1 | HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | MDM2, TP53, CDKN1A | MRGPRX1 4275/4885TSPO 4182/4885MAP2K4 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.